The Ends of Lecirelin on the Destruction of Ovarian Cancer Cells
International Pharmacy Acta · 16.11.2024
DOI: 10.22037/ipa.v7i1.46123 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Pharmacy Acta, erschienen am 16.11.2024. Verfasst von Fatemeh Tahoori und 1 weiteren Autor:innen.
Abstract (Originalsprache)
As a gynecological cancer, ovarian cancer has the highest lethality among females on the globe. Evidence shows that the GnRH agonists and antagonists dramatically inhibit the growth of most cancer cell lines expressing the GnRH receptor. The current research focuses on the effectiveness of three novel GnRH analogs showing anticancer activities on the cell lines of ovarian cancer. The present investigation synthesized Lecirelin in the solid phase and changed the peptide chain’s C-terminal. Two ovarian cancer cell lines were examined for the impacts of the purified peptides. The hydrazide derivative with an approximate concentration of 30 mg/mL (lC50~30) can kill more than half of the ovarian cancer cells, while the Lecirline needs twice more active ingredient to kill this amount of the cells (lC50~47, p = 0.001). Lecirelin and its hydrazide derivative have anticancer activity against ovarian cancer cells, and this GnRH analog may be considered a promising candidate for further studies.
Schlagwörter
Zitieren
APA
Tahoori, F., & Salehi-Najafabadi, Z. (2024). The Ends of Lecirelin on the Destruction of Ovarian Cancer Cells. International Pharmacy Acta. https://doi.org/10.22037/ipa.v7i1.46123
Vancouver
Tahoori F, Salehi-Najafabadi Z. The Ends of Lecirelin on the Destruction of Ovarian Cancer Cells. International Pharmacy Acta. 2024. doi:10.22037/ipa.v7i1.46123
BibTeX
@article{Tahoori2024,
author = {Tahoori, Fatemeh and Salehi-Najafabadi, Zahra},
title = {The Ends of Lecirelin on the Destruction of Ovarian Cancer Cells},
journal = {International Pharmacy Acta},
year = {2024},
doi = {10.22037/ipa.v7i1.46123}
}
EUVIMED